secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kura Oncology, Inc. (KURA)
CIK:        0001422143
Form:       8-K
Filed at:   2025-05-01T23:59:59+00:00
Accession:  0000950170-25-061836
Event type: earnings
Sentiment:  positive
Materiality: 0.73
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kura Oncology Q1 net loss $57.4M; NDA submitted for ziftomenib, $45M milestone earned
--------------------------------------------------------------------------------

- NDA for ziftomenib in R/R NPM1-mutant AML submitted March 31, 2025; FDA review period expected Q2 2025.
- Earned $45 million milestone from Kyowa Kirin for NDA submission; pro forma cash $703.2M.
- Q1 collaboration revenue $14.1M (vs $0 in Q1 2024); R&D expenses $56.0M, up 54% YoY.
- Cash, equivalents and short-term investments $658.2M at March 31, 2025; runway into 2027.
- First patients dosed in Phase 1 trial of ziftomenib plus imatinib in GIST; data at ASCO and EHA upcoming.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422143/000095017025061836/0000950170-25-061836-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422143/000095017025061836/kura-20250501.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-061836

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer